Senior Correspondent, London
Ben's Feed
Dec 19, 2014
Dec 19, 2014

Double blow for Roche as Alzheimer’s, breast cancer studies fail

ZURICH/LONDON, Dec 19 (Reuters) – Roche said on
Friday it would discontinue a late-stage study of an
experimental Alzheimer’s drug after it failed to prove
effective, underlying the difficulty of treating the
memory-robbing disease.

The Swiss drugmaker also said a breast cancer trial had
failed to demonstrate the benefit of adding its new drug Kadcyla
to treatment programmes.

Dec 18, 2014
Dec 18, 2014

New GSK shingles vaccine may challenge Merck after strong test data

LONDON (Reuters) – An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group’s expanding vaccine unit a potential $1 billion boost.

The data suggests the British company’s new shot could be a strong competitor for Merck & Co’s established vaccine Zostavax, which is currently the only product on the market.

Dec 18, 2014
Dec 18, 2014

EU’s top court opens door to some stem cell patents

BRUSSELS/LONDON (Reuters) – Europe’s top court has opened the door to certain stem cell patents in the European Union by ruling that an organism incapable of developing into a human being is not a human embryo and may be patented.

Thursday’s judgment by the European Court of Justice was made following a case brought in Britain by U.S. company International Stem Cell Corporation over whether it could patent processes covering the use of human egg cells.

Dec 18, 2014
Dec 18, 2014
Dec 18, 2014
Dec 17, 2014
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben